Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
AbCellera Biologics Inc. (ABCL) had Income from Continuous Operations of $-43.16M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$8.31M |
|
$-43.16M |
|
-- |
|
$8.31M |
|
$65.83M |
|
$-57.52M |
|
$7.98M |
|
$-49.54M |
|
$-49.54M |
|
$-43.16M |
|
|
Income from Continuous Operations |
$-43.16M |
$-43.16M |
|
$-43.16M |
|
$-57.52M |
|
$-48.86M |
|
303.07M |
|
303.07M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$664.60M |
|
$422.81M |
|
$642.52M |
|
$1.31B |
|
$47.29M |
|
-- |
|
$321.74M |
|
$369.03M |
|
$938.08M |
|
$852.82M |
|
$938.08M |
|
303.95M |
|
| Cash Flow Statement Financials | |
$-33.52M |
|
$-25.08M |
|
$7.19M |
|
$155.25M |
|
$103.80M |
|
$-51.45M |
|
$12.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-691.75% |
|
-691.75% |
|
-- |
|
-595.75% |
|
-519.12% |
|
$-37.35M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.23 |
|
397.89 |
|
-4.60% |
|
-5.06% |
|
-3.30% |
|
-4.60% |
|
$3.09 |
|
$-0.12 |
|
$-0.11 |
|